Understanding a Gene Called Six1 in Lung Scarring
Sineoculis Homeobox Homolog 1 (Six1) in Pulmonary Fibrosis
This research explores how a specific gene, Six1, contributes to the development of lung scarring in people with Idiopathic Pulmonary Fibrosis, hoping to find new ways to help.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11061010 on NIH RePORTER |
What this research studies
Idiopathic Pulmonary Fibrosis (IPF) is a serious lung condition where scar tissue builds up, making it hard to breathe. Current treatments can slow the disease but don't stop or reverse it, so new approaches are urgently needed. Our team has found that a gene called Six1 is more active in IPF and seems to play a role in how lung cells change and contribute to scarring. We are studying how Six1 affects lung cells and whether blocking its activity could prevent or reduce lung scarring.
Who could benefit from this research
Good fit: This foundational research is for patients with Idiopathic Pulmonary Fibrosis who are interested in understanding the underlying causes of their condition and the development of future therapies.
Not a fit: Patients seeking immediate treatment options or direct clinical intervention will not receive benefit from this early-stage laboratory research.
Why it matters
Potential benefit: If successful, this work could lead to the discovery of new medications that target the Six1 gene to better treat or even reverse lung scarring in patients with Idiopathic Pulmonary Fibrosis.
How similar studies have performed: While current treatments for IPF exist, this approach of targeting the Six1 gene is novel and has shown promising results in experimental models, suggesting a new pathway for intervention.
Where this research is happening
Houston, United States
- University of Texas Hlth Sci Ctr Houston — Houston, United States (Active)
Researchers
- Principal investigator: Karmouty-Quintana, Harry — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Karmouty-Quintana, Harry
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.